SEC Form 4 · accession 0001493152-16-016102
HARROW, INC. · HROW
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark L Baum
Officer — Chief Executive Officer · Director
Period of report
Dec 19, 2016
Accepted (ET)
Dec 21, 2016 · 4:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001360214
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 19, 2016 | P | 156,000 | $1.79 | A | 325,835 | D | |
| Common StockF2 | Dec 19, 2016 | M | 200,000 | $1.72 | A | 525,835 | D | |
| Common StockF2 | Dec 19, 2016 | D | 83,709 | $1.72 | D | 442,126 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Purchase WarrantF3 | $1.79 | Dec 19, 2016 | P | 156,000 | A | Jun 23, 2016 | Dec 23, 2019 | Common Stock | 156,000 | 156,000 | D |
| Restricted Stock UnitF2 | $0.00 | Dec 19, 2016 | M | 200,000 | D | — | — | Common Stock | 200,000 | 0 | D |
Explanation of responses
- F1On December 19, 2016, the Beadore Trust dated March 20, 2015, through which Mr. Baum has voting and investment control over the securities, entered into a definitive agreement to acquire 156,000 Units of Imprimis Pharmaceuticals, Inc.'s (the "Company"), with each Unit consisting of one share of common stock, and a warrant to purchase one share of the Company's common stock, as part of a private placement by the Company to accredited investors.
- F2On December 19, 2016, restricted stock units granted to Mr. Baum on May 2, 2013, and previously vested, were issued and then transferred into the Beadore Trust dated March 20, 2015. 83,709 shares of common stock were withheld from issuance to Mr. Baum for payroll tax purposes.
- F3The value of the Purchase Warrant included in each Unit is $0.125.